Novartis Pharmaceuticals Corp v. Secretary United States Department of Health, et al
Case Number:
24-2968
Court:
Nature of Suit:
Companies
- AARP Inc.
- American College of Physicians
- American Public Health Association
- American Society of Hematology
- Center for American Progress
- Center for Medicare Advocacy Inc.
- Justice in Aging
- Public Citizen Inc.
- UnidosUS
Government Agencies
Sectors & Industries:
-
September 16, 2025
Pharma Tests Drug Price Policies In Court: 3 Cases To Know
Two circuit courts issued notable rulings over the past week upholding laws aimed at lowering prescription drug prices. Elsewhere, insulin makers are seeking a panel rehearing in a proposed class action targeting discount programs. Here, Law360 Healthcare Authority looks at three key drug pricing cases you may have missed.
-
September 11, 2025
Medicare Drug Pricing Plan Survives Novartis' 3rd Circ. Appeal
The Third Circuit ruled Thursday that the Centers for Medicare & Medicaid Services' ability to negotiate "maximum fair prices" with drugmakers doesn't violate their constitutional rights, rejecting an argument by Novartis Pharmaceuticals Corp. that the practice amounted to a raw deal for the pharmaceutical industry.
-
April 08, 2025
Medicare Drug Price Plan Tramples Constitution, 3rd Circ. Told
New Jersey federal court rulings preserving the Centers for Medicare & Medicaid Services' ability to negotiate prices with drug companies should be overturned on constitutional grounds, pharmaceutical giants Novo Nordisk and Novartis told the Third Circuit during oral arguments Tuesday.
-
March 12, 2025
Law360 Cheat Sheet: Novartis' Fight Over Generic Entresto
Novartis has led a wide-ranging litigation campaign to block generic versions of its bestselling cardiovascular drug Entresto that has involved multidistrict litigation, trips to several circuit courts and cases against the federal government. Here, Law360 breaks down how the various cases intersect and what's still playing out.
-
February 25, 2025
Trump Administration In Court: ACA, Trans Care, Drug Pricing
Directives from the White House threatening gender-affirming care, medical research funding and employment across federal health agencies met resistance in recent days as courts ruled to halt enforcement and states and labor groups filed for injunctive relief.